This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Söderbergh, A. Articles by Husebye, E. S. Search for Related Content PubMed PubMed Citation Articles by Söderbergh, A. Articles by Husebye, E. S.

Autoantibodies against Aromatic L-Amino Acid Decarboxylase Identifies a Subgroup of Patients with Addison’s Disease¹

Department of Clinical Sciences (A.S., F.R., O.E., O.K.), University Hospital, SE-751 85 Uppsala, Sweden; Hospital for Children and Adolescence (M.H.), Helsinki University Hospital, FIN-00290 Helsinki, Finland; Department of Human Molecular Genetics (P.B.), Finland National Public Health Institute, FIN-00300, Helsinki, Finland; and Division of Endocrinology, Institute of Medicine (E.S.H.), Haukeland University Hospital, N-5021 Bergen, Norway

Address correspondence and requests for reprints to: Annika Söderbergh, M.D., Department of Medical Sciences, University Hospital, Uppsala University, SE-751 85 Uppsala, Sweden. E-mail: annika.soderbergh{at}medicin.uu.se

Autoantibodies against aromatic L-amino acid decarboxylase (AADC) are present in about 50 percent of sera from patients with autoimmune polyendocrine syndrome type I (APS I) but absent in sera from patients with different organ-specific autoimmune diseases, such as insulin-dependent diabetes mellitus, Hashimoto’s thyroiditis, and Graves’ disease. AADC is expressed in the pancreatic ß-cells, the liver, and the nervous system; and the presence of AADC antibodies has been shown to correlate to hepatitis and vitiligo in APS I patients.

Among 101 investigated patients with autoimmune Addison’s disease, 15 had high titers of AADC antibodies. According to the clinical characteristics of these patients, only 3 had APS I. The remaining 12 had either isolated Addison’s disease or associated diabetes mellitus, hypothyroidism, vitiligo, alopecia, gonadal failure, and pernicious anemia. Autoantibodies against 21-hydroxylase were present in 9 of 12, whereas autoantibodies against side-chain cleavage enzyme and 17-hydroxylase were present in 3 of 12. Two patients had only autoantibodies against AADC. DNA was available from 3 of these 12 patients. One of the patients, a woman with Addison’s disease, autoimmune thyroiditis, and premature menopause was heterozygous for a point mutation (G1021A, Val301Met) in the first plant homeodomain zinc finger domain of the autoimmune regulator (AIRE) gene.

The presence of AADC autoantibodies identifies patients with APS I and a subgroup of Addison patients who may have a milder atypical form of APS I or represent a distinct entity. Measurement of autoantibodies against AADC should be included in the evaluation of Addison’s disease.

This article has been cited by other articles:

				K. T. Podkrajsek, T. Milenkovic, R. J Odink, H. L Claasen-van der Grinten, N. Bratanic, T. Hovnik, and T. Battelino Detection of a complete autoimmune regulator gene deletion and two additional novel mutations in a cohort of patients with atypical phenotypic variants of autoimmune polyglandular syndrome type 1 Eur. J. Endocrinol., November 1, 2008; 159(5): 633 - 639. [Abstract] [Full Text] [PDF]

				A. S. Koh, A. J. Kuo, S. Y. Park, P. Cheung, J. Abramson, D. Bua, D. Carney, S. E. Shoelson, O. Gozani, R. E. Kingston, et al. Aire employs a histone-binding module to mediate immunological tolerance, linking chromatin regulation with organ-specific autoimmunity PNAS, October 14, 2008; 105(41): 15878 - 15883. [Abstract] [Full Text] [PDF]

				P. Candeloro, C. B. Voltattorni, R. Perniola, M. Bertoldi, C. Betterle, M. Mannelli, R. Giordano, A. De Bellis, C. Tiberti, S. Laureti, et al. Mapping of Human Autoantibody Epitopes on Aromatic L-Amino Acid Decarboxylase J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1096 - 1105. [Abstract] [Full Text] [PDF]

				A. S. B. Wolff, M. M. Erichsen, A. Meager, N. F. Magitta, A. G. Myhre, J. Bollerslev, K. J. Fougner, K. Lima, P. M. Knappskog, and E. S. Husebye Autoimmune Polyendocrine Syndrome Type 1 in Norway: Phenotypic Variation, Autoantibodies, and Novel Mutations in the Autoimmune Regulator Gene J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 595 - 603. [Abstract] [Full Text] [PDF]

				R. Perry, O. Kecha, J. Paquette, C. Huot, G. Van Vliet, and C. Deal Primary Adrenal Insufficiency in Children: Twenty Years Experience at the Sainte-Justine Hospital, Montreal J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3243 - 3250. [Abstract] [Full Text] [PDF]

				A. Soderbergh, A. G. Myhre, O. Ekwall, G. Gebre-Medhin, H. Hedstrand, E. Landgren, A. Miettinen, P. Eskelin, M. Halonen, T. Tuomi, et al. Prevalence and Clinical Associations of 10 Defined Autoantibodies in Autoimmune Polyendocrine Syndrome Type I J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 557 - 562. [Abstract] [Full Text] [PDF]

				A. Meloni, R. Perniola, V. Faa, E. Corvaglia, A. Cao, and M. C. Rosatelli Delineation of the Molecular Defects in the AIRE Gene in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Patients from Southern Italy J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 841 - 846. [Abstract] [Full Text] [PDF]

				V. Kumar, M. Rajadhyaksha, and J. Wortsman Celiac Disease-Associated Autoimmune Endocrinopathies Clin. Vaccine Immunol., July 1, 2001; 8(4): 678 - 685. [Abstract] [Full Text] [PDF]

				O. Ekwall, J. Haavik, J. Perheentupa, C. Betterle, J. Gustafsson, E. Husebye, F. Rorsman, and O. Kämpe Pteridin-Dependent Hydroxylases as Autoantigens in Autoimmune Polyendocrine Syndrome Type I J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2944 - 2950. [Abstract] [Full Text]